Schrödinger, Inc. (NASDAQ:SDGR) is one of the best healthcare AI stocks to buy now. On December 15, BofA Securities upgraded ...

Earlier in December 2025, BofA Securities upgraded Schrödinger, Inc. after the company shifted away from internal drug development to concentrate on its core computational software business. This ...

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, is providing a detailed review of ...

Schrodinger shares came under pressure after Citi pulled back its bullish call, cutting the stock to ‘Neutral’ from ‘Buy’ and slashing its price target to $20 from $35. The firm said recent stumbles ...

Schrödinger, a little-known software company that helps some of the largest pharmaceutical brands with drug discovery, made its public debut. The company closed its initial public offering on Monday, ...

Schrodinger is a biotech company that uses machine learning, physics, and chemistry to speed up the drug discovery process, focusing on finding ligands that bind with proteins to treat diseases. The ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the third quarter of 2024 and provided a business update. In a separate press release issued earlier ...

A project to improve data visualization ended up overturning a century-old model of color space that underpins industry standards for color everywhere from digital displays to paint. The opportunity ...

Eli Lilly has joined Schrödinger’s growing stable of drug development partners, putting up $425 million in milestones to access small-molecule candidates against an undisclosed target. Schrödinger has ...